

Translational Immunological Seminar

Lecture series as part of the training in Immunology (DGfI)

January 18th 2018 at 3.00 pm

Lecture hall B15, building 32, entrance C (Children's Hospital)

„Translational Immunology: more than a scientific challenge“

Prof. Dr. Helmut R. Salih

**Professor for Translational Immunology
University Tübingen**

**Head of the Clinical Collaboration Unit Translational
Immunology**

German Cancer Consortium (DKTK), DKFZ, Heidelberg



Prof. Dr. Helmut Salih studied Medicine at the University of Munich, where he also graduated. During his subsequent post-doctoral training, he worked 2 years at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ, and then continued both his research and medical training at the Department of Hematology of the University Tübingen. In 2014, he was appointed Chair (W3 Professor) for Translational Immunology at the University Tübingen and became Head of the Clinical Collaboration Unit Translational Immunology at the German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg. His translational interests focus on the development of monoclonal and bispecific antibodies as well as peptide vaccination strategies to reinforce antitumor immunity in cancer patients. Notably, particular effort is made to develop novel therapeutics (i) until the stage of clinical application with (ii) substantial contribution of academia, as exemplified by two recently initiated clinical first in-man-studies evaluating a personalized peptide vaccine in patients with CLL (EUDRA-CT-No. 2015-005817-61) and an Fc-optimized FLT3 antibody for elimination of MRD in patients with AML (clinicaltrials.gov, NCT02789254). Helmut Salih holds several patents in this field and has received several awards for his research and clinical achievements.

Organizers: Prof. Dr. Evelyn Ullrich, Prof. Dr. Heinfried Radeke, Prof. Dr. Alexander Steinle, Prof. Dr. Andreas Krueger

Contact: Prof. Dr. Alexander Steinle (alexander.steinle@kgu.de)